



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville MD 20857

**FILE COPY**

June 3, 2013

Alan G. Minsk  
Arnall Golden Gregory LLP  
171 17<sup>th</sup> Street, N.W.  
Suite 2100  
Atlanta, Georgia 30363

Dear Mr. Minsk:

Your petition to the Food and Drug Administration requesting to Determine that the drug Intal® (cromolyn sodium) Inhalation Capsule, 20 mg New Drug Application #016990 was voluntarily withdrawn from the market for reasons other than safety or effectiveness, was received by this office on 06/03/2013. It was assigned docket number FDA-2013-P-0665/CP1, and it was filed on 06/03/2013. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Gloria Ortega  
Administrative Proceedings Officer  
Division of Dockets Management  
FDA/Office of the Executive Secretariat (OES)

*FDA-2013-P-0665*

*ACK*